Laura Chico
Stock Analyst at Wedbush
(3.69)
# 745
Out of 5,156 analysts
241
Total ratings
47.88%
Success rate
7.66%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Reiterates: Outperform | $24 | $14.05 | +70.82% | 4 | Mar 9, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $12 → $14 | $7.18 | +94.99% | 2 | Mar 6, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $11 → $12 | $5.22 | +129.89% | 5 | Mar 3, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $18 | $20.07 | -10.31% | 15 | Feb 25, 2026 | |
| GOSS Gossamer Bio | Downgrades: Neutral | $6 → $1 | $0.50 | +99.72% | 7 | Feb 24, 2026 | |
| ARDX Ardelyx | Reiterates: Outperform | $19 | $6.19 | +206.95% | 16 | Feb 23, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $95 → $130 | $310.71 | -58.16% | 12 | Feb 20, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $25 | $21.25 | +17.65% | 15 | Feb 17, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $149 → $151 | $128.13 | +17.85% | 11 | Feb 12, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $46 → $55 | $65.20 | -15.64% | 12 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $187 | $184.87 | +1.15% | 20 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $35.48 | +1.47% | 9 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $19.69 | +52.36% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $39.07 | -15.54% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $47 | $28.34 | +65.84% | 8 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $30 | $25.91 | +15.79% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $44.83 | -19.70% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $32 | $27.82 | +15.03% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $5.69 | +40.72% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $6.75 | +107.41% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $41.94 | +2.53% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $27.24 | +17.47% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.48 | +112.26% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $20.76 | -80.73% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.91 | +57.07% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.90 | +79.49% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $10.91 | +706.60% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $10.05 | -50.25% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $61.12 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.57 | +9.41% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.92 | +1,396.98% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.01 | +8,888.76% | 1 | Jan 19, 2018 |
Jade Biosciences
Mar 9, 2026
Reiterates: Outperform
Price Target: $24
Current: $14.05
Upside: +70.82%
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $12 → $14
Current: $7.18
Upside: +94.99%
Larimar Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $11 → $12
Current: $5.22
Upside: +129.89%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $20.07
Upside: -10.31%
Gossamer Bio
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.50
Upside: +99.72%
Ardelyx
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $6.19
Upside: +206.95%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $310.71
Upside: -58.16%
Ultragenyx Pharmaceutical
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $21.25
Upside: +17.65%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Outperform
Price Target: $149 → $151
Current: $128.13
Upside: +17.85%
Dianthus Therapeutics
Feb 11, 2026
Maintains: Outperform
Price Target: $46 → $55
Current: $65.20
Upside: -15.64%
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $184.87
Upside: +1.15%
Jan 12, 2026
Maintains: Outperform
Price Target: $32 → $36
Current: $35.48
Upside: +1.47%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $19.69
Upside: +52.36%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $39.07
Upside: -15.54%
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $28.34
Upside: +65.84%
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $25.91
Upside: +15.79%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $44.83
Upside: -19.70%
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $27.82
Upside: +15.03%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.69
Upside: +40.72%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $6.75
Upside: +107.41%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $41.94
Upside: +2.53%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $27.24
Upside: +17.47%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.48
Upside: +112.26%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $20.76
Upside: -80.73%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.91
Upside: +57.07%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.90
Upside: +79.49%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $10.91
Upside: +706.60%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $10.05
Upside: -50.25%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $61.12
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.57
Upside: +9.41%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.92
Upside: +1,396.98%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.01
Upside: +8,888.76%